Cargando…

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

BACKGROUND: We evaluated treatment decisions and outcomes in a cohort of predominately Caucasian patients with EGFR mutation-positive (EGFR Mut+) non-small-cell lung cancer (NSCLC). METHODS: REASON (NCT00997230) was a non-interventional study in German patients with stage IIIB/IV NSCLC. Secondary en...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schuette, Wolfgang, Schirmacher, Peter, Eberhardt, Wilfried E. E., Dietel, Manfred, Zirrgiebel, Ute, Muehlenhoff, Lars, Thomas, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799904/ https://www.ncbi.nlm.nih.gov/pubmed/29402243 http://dx.doi.org/10.1186/s12885-018-4032-3

Ejemplares similares

Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life
por: Schuette, Wolfgang, et al.
Publicado: (2012)

Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain
por: Morlock, Robert, et al.
Publicado: (2017)

Pharmacoeconomic considerations in the treatment of breast cancer
por: Pallis, Athanasios, et al.
Publicado: (2010)

Pharmacoeconomic evaluations in the treatment of actinic keratoses
por: Tolley, Keith, et al.
Publicado: (2017)

Brain metastases in ALK-positive NSCLC – time to adjust current treatment algorithms
por: Griesinger, Frank, et al.
Publicado: (2018)

Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence
por: Pöttgen, Christoph, et al.
Publicado: (2017)

Pharmacoeconomic aspects of the treatment of pituitary gland tumours
por: Sowiński, Jerzy, et al.
Publicado: (2013)

Essentials of pharmacoeconomics
por: Rascati, Karen L.
Publicado: (2014)

Principles of pharmacoeconomics /
Publicado: (1996)

A review of the pharmacoeconomics of eletriptan for the acute treatment of migraine
por: Bhambri, Rahul, et al.
Publicado: (2015)

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
por: Ninomiya, Kiichiro, et al.
Publicado: (2020)

Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina
por: Elgart, Jorge F, et al.
Publicado: (2013)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
por: Kuiper, J L, et al.
Publicado: (2016)

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC
por: Roeper, Julia, et al.
Publicado: (2020)

Haemophilia A: Pharmacoeconomic Review of Prophylaxis Treatment versus On-Demand
por: Unim, Brigid, et al.
Publicado: (2015)

Pharmacoeconomic evaluation of treatment effectiveness with selected biologic treatment in rheumatoid arthritis therapy
por: Kowalik, Krzysztof, et al.
Publicado: (2018)

Perspective on the Cardiotoxicity of Third-Generation Targeted EGFRs in the Treatment of NSCLC
por: Ewer, Michael S., et al.
Publicado: (2021)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
por: Castrop, Florian, et al.
Publicado: (2013)

Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment
por: Kowalik, Krzysztof, et al.
Publicado: (2018)

Need for pharmacoeconomic consideration of antiepileptic drugs monotherapy treatment in persons with epilepsy
por: Sarangi, Sudhir C., et al.
Publicado: (2020)

The pharmacoeconomics of the state-of-the-art drug treatments for asthma: a systematic review
por: Menzella, Francesco, et al.
Publicado: (2021)

Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol
por: Vormfelde, Stefan Viktor, et al.
Publicado: (2016)

The current treatment landscape in the UK for stage III NSCLC
por: Evison, Matthew
Publicado: (2020)

Pharmacoeconomics in COPD: lessons for the future
por: Starkie, Helen J, et al.
Publicado: (2008)

Fluid management: the pharmacoeconomic dimension
por: Vincent, Jean-Louis
Publicado: (2000)

Drug Policy Research & Pharmacoeconomics
Publicado: (2008)

Development of pharmacoeconomics guidelines for India
por: Thomas, Dixon, et al.
Publicado: (2014)

Formulary Management Methods and Pharmacoeconomics
por: Curtiss, Frederic R.
Publicado: (2003)

Pharmacoeconomic Benefits of Antihypertensive Therapy
por: Gonzalez, Edgar R.
Publicado: (2007)

Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
por: Wu, Xuan, et al.
Publicado: (2013)

Mechanism of Xu Li's Experiential Prescription for the Treatment of EGFR-Positive NSCLC
por: Xu, Bin, et al.
Publicado: (2020)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)

An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC
por: Huang, Yanping, et al.
Publicado: (2023)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
por: Skrzypski, Marcin, et al.
Publicado: (2017)

Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies
por: Krueger, Kem P, et al.
Publicado: (2009)

An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia
por: Piena, Marjanne A., et al.
Publicado: (2021)

Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes
por: Su, Yu, et al.
Publicado: (2023)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC
por: Goldberg, Michael E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j4bvm2rhmjnqpchh958su5li1u